Editorial

Year brings higher impact factor, more submissions for *Neuro-Oncology*

We are delighted to report that *Neuro-Oncology* experienced yet another year of growth and success in 2012.

**Impact Factor and Rankings**

The journal’s focus on quality contributed to its most recent impact factor of 5.723 (Figure 1). This score is particularly exciting because it is the first to reflect our change to monthly publication in 2010. *Neuro-Oncology* is now ranked 22 of 194 oncology journals and 15 of 191 clinical neurology journals.

**Increase in Submitted and Published Articles**

We are also pleased to report a substantial increase in the number of new submissions in 2012, with a projected 905 new and revised manuscripts (672 new and 233 revised). This total represents an increase of 35% over the previous year. From January 1 through October 31, 130 papers were accepted for publication. Our acceptance rate of approximately 19% reflects our continued dedication to publishing only the most significant research.

Through the December issue, *Neuro-Oncology* published 149 articles in 1528 pages (versus 102 in 1380 pages in 2011). As of October 31, we had received manuscripts from 37 countries. Approximately half of all accepted papers were from the United States and Canada; 31% were from Europe, 15% were from Asia, and the remainder were from other countries (including Central and South America and Australia). The percentage of submissions from Asia also increased, from 20% in 2011 to 25%.

**Volume 15 News**

As we reported in the June 2012 issue of *Neuro-Oncology* (1), a substantial percentage of the cell lines used in medical research are contaminated or misidentified. To help address this issue, beginning in volume 15, we will begin requiring a statement of cell line validation in all manuscripts in which cell lines are used. This policy is similar to that in place for all American Association for Cancer Research journals, among others. All authors should describe their validation methods or briefly explain why validation was not needed. We ask all peer reviewers to be vigilant about this issue when evaluating submitted work.

**Peer and Statistical Reviewers**

*Neuro-Oncology* is indebted to the members of its editorial board (whose names appear in every issue of the journal) and its numerous peer and statistical reviewers, all of whom have helped it along its path to success. Listed below are reviewers who had agreed to conduct manuscript reviews as of September 30. The staff apologizes for any inadvertent omissions.

Roger Abounader  
Manish Aghi  
Yukinori Akiyama  
Francis Ali-Osman  
James Angelastro  
Terri Armstrong  
Ute Bartels  
Elizabeth Beierle  
Michael Berens  
Jaclyn Biegel  
Stefan Bluml

---

Fig. 1. *Neuro-Oncology*’s impact factors, 2002–2011. The impact factor, published annually by Thomson Scientific in the Journal Citation Reports, is determined using article citation rates and is used to measure journal quality.

© The Author(s) 2012. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Reference


W.K. Alfred Yung
Editor-in-Chief